FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
The FDA approved Hepcludex (bulevirtide-gmod) injection for the treatment of chronic hepatitis delta virus (HDV) infection in adult patients either without cirrhosis or with compensated cirrhosis.
This approval affects the manufacturer of Hepcludex, healthcare providers treating chronic HDV, and regulatory professionals managing liver disease portfolios.
This represents a significant regulatory milestone as the first FDA-approved therapeutic specifically for HDV, a condition with historically limited treatment options. The narrow indication (excluding decompensated cirrhosis) suggests that clinical teams must maintain rigorous patient screening and monitoring protocols to align with the approved labeling and safety profile.
Regulatory and clinical teams should update HDV treatment protocols to reflect the availability of this first-in-class agent and ensure labeling compliance regarding the specified patient populations (non-cirrhotic or compensated cirrhotic adults). QA teams should review manufacturing and distribution controls for this new subcutaneous injection.
Today, the U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis (advanced liver scarring) or with compensated cirrhosis.
Open in openFDA / FDA.gov